KRAS and ameloblastoma: It is notable that the presence of two or three gene mutations, including somatic mutations in KRAS, PIK3CA, PTEN, FGFR, CDKN2A, and CTNNB1 in the background of either BRAF or SMO mutation-positive ameloblastomas, exclusively occurred in solid/conventional tumors [55].